Free Trial

Ultragenyx Pharmaceutical (RARE) Competitors

Ultragenyx Pharmaceutical logo
$35.41 -1.94 (-5.19%)
Closing price 04:00 PM Eastern
Extended Trading
$35.42 +0.01 (+0.01%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RARE vs. GMAB, RDY, VTRS, MRNA, QGEN, ASND, ROIV, RVMD, BBIO, and BPMC

Should you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Moderna (MRNA), Qiagen (QGEN), Ascendis Pharma A/S (ASND), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.

Ultragenyx Pharmaceutical vs.

Genmab A/S (NASDAQ:GMAB) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends.

Genmab A/S has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.

Ultragenyx Pharmaceutical received 672 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 77.54% of users gave Ultragenyx Pharmaceutical an outperform vote while only 63.02% of users gave Genmab A/S an outperform vote.

CompanyUnderperformOutperform
Genmab A/SOutperform Votes
167
63.02%
Underperform Votes
98
36.98%
Ultragenyx PharmaceuticalOutperform Votes
839
77.54%
Underperform Votes
243
22.46%

Genmab A/S has a net margin of 36.30% compared to Ultragenyx Pharmaceutical's net margin of -101.60%. Genmab A/S's return on equity of 16.78% beat Ultragenyx Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Genmab A/S36.30% 16.78% 13.79%
Ultragenyx Pharmaceutical -101.60%-193.80%-38.15%

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Genmab A/S had 4 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 20 mentions for Genmab A/S and 16 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.12 beat Genmab A/S's score of 0.70 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
8 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ultragenyx Pharmaceutical
14 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Genmab A/S presently has a consensus target price of $39.17, suggesting a potential upside of 92.65%. Ultragenyx Pharmaceutical has a consensus target price of $90.93, suggesting a potential upside of 143.46%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69
Ultragenyx Pharmaceutical
0 Sell rating(s)
1 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.93

Genmab A/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$3.12B4.18$1.14B$1.7611.55
Ultragenyx Pharmaceutical$590.69M5.98-$569.18M-$5.88-6.35

Summary

Genmab A/S beats Ultragenyx Pharmaceutical on 10 of the 19 factors compared between the two stocks.

Get Ultragenyx Pharmaceutical News Delivered to You Automatically

Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RARE vs. The Competition

MetricUltragenyx PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.53B$6.54B$5.43B$8.48B
Dividend YieldN/A2.66%5.22%4.11%
P/E Ratio-5.899.1426.7920.05
Price / Sales5.98255.59395.67116.44
Price / CashN/A65.8538.2534.62
Price / Book13.536.546.864.61
Net Income-$569.18M$143.51M$3.22B$248.19M
7 Day Performance7.57%5.60%6.80%2.97%
1 Month Performance5.51%10.06%13.69%16.58%
1 Year Performance-7.96%-0.86%18.25%8.16%

Ultragenyx Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RARE
Ultragenyx Pharmaceutical
3.9661 of 5 stars
$35.41
-5.2%
$90.93
+156.8%
-10.1%$3.35B$590.69M-5.591,310Positive News
GMAB
Genmab A/S
3.4467 of 5 stars
$19.91
+2.8%
$39.17
+96.8%
-31.5%$12.76B$21.64B11.441,660News Coverage
High Trading Volume
RDY
Dr. Reddy's Laboratories
2.3333 of 5 stars
$13.93
+3.9%
$17.00
+22.1%
+5.3%$11.62B$311.31B22.1724,800Positive News
Gap Up
VTRS
Viatris
2.0946 of 5 stars
$8.95
+2.0%
$10.50
+17.4%
-19.8%$10.61B$14.33B-12.0937,000Trending News
Gap Up
MRNA
Moderna
4.4677 of 5 stars
$25.68
+5.9%
$53.95
+110.1%
-80.2%$9.93B$3.14B-2.773,900News Coverage
Gap Up
QGEN
Qiagen
4.0353 of 5 stars
$42.92
+2.5%
$48.42
+12.8%
-3.4%$9.54B$1.98B119.526,030Positive News
ASND
Ascendis Pharma A/S
3.521 of 5 stars
$154.93
+2.4%
$216.07
+39.5%
+33.5%$9.45B$368.70M-21.82640
ROIV
Roivant Sciences
1.9915 of 5 stars
$10.98
+3.1%
$17.50
+59.5%
-2.9%$7.83B$122.59M-73.16860Positive News
RVMD
Revolution Medicines
4.4108 of 5 stars
$41.85
+3.5%
$67.17
+60.5%
+1.1%$7.79B$742,000.00-11.66250Positive News
BBIO
BridgeBio Pharma
4.6002 of 5 stars
$35.65
+4.3%
$57.09
+60.1%
+14.2%$6.77B$127.42M-12.51400Positive News
Insider Trade
BPMC
Blueprint Medicines
2.6687 of 5 stars
$100.24
+3.2%
$126.56
+26.3%
-1.2%$6.47B$562.12M-92.81640Positive News

Related Companies and Tools


This page (NASDAQ:RARE) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners